--- title: "IAS、MODV 和 TIXT 的最後期限提醒：Frank R. Cruz 律師事務所提醒投資者代表股東提起集體訴訟" description: "弗蘭克·R·克魯茲律師事務所已宣佈對 Integral Ad Science (IAS)、ModivCare (MODV) 和 TELUS International (TIXT) 的股東提起集體訴訟。投資者必須在 2025 年 3 月 31 日之前提交首席原告動議。訴訟指控這些公司在其業務運營和財務健康方面發表了誤導性聲明，影響了股東的投資。遭受損失的股東被鼓勵聯繫該律師事務所尋求幫助" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/232111335.md" published_at: "2025-03-17T15:09:28.000Z" --- # IAS、MODV 和 TIXT 的最後期限提醒：Frank R. Cruz 律師事務所提醒投資者代表股東提起集體訴訟 > 弗蘭克·R·克魯茲律師事務所已宣佈對 Integral Ad Science (IAS)、ModivCare (MODV) 和 TELUS International (TIXT) 的股東提起集體訴訟。投資者必須在 2025 年 3 月 31 日之前提交首席原告動議。訴訟指控這些公司在其業務運營和財務健康方面發表了誤導性聲明，影響了股東的投資。遭受損失的股東被鼓勵聯繫該律師事務所尋求幫助 LOS ANGELES, March 17, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. **Integral Ad Science Holding Corp.** (NASDAQ: IAS) Class Period: March 2, 2023 – February 27, 2024 Lead Plaintiff Deadline: **March 31, 2025** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (2) that IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (3) that pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you are an Integral Ad Science shareholder who suffered a loss, click here to participate. **ModivCare, Inc.** (NASDAQ: MODV) Class Period: November 3, 2022 – September 15, 2024 Lead Plaintiff Deadline: **March 31, 2025** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate; (2) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (3) the Company had insufficient liquidity; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you are a ModivCare shareholder who suffered a loss, click here to participate. **TELUS International (Cda) Inc.** (NYSE: TIXT) Class Period: February 16, 2023 – August 1, 2024 Lead Plaintiff Deadline: **March 31, 2025** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) that Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) that Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are a TELUS shareholder who suffered a loss, click here to participate. Follow us for updates on Twitter: twitter.com/FRC\_LAW. To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. **Contacts** The Law Offices of Frank R. Cruz, Los Angeles Frank R. Cruz, 310-914-5007 fcruz@frankcruzlaw.com www.frankcruzlaw.com ### Related Stocks - [MODV.US - ModivCare](https://longbridge.com/zh-HK/quote/MODV.US.md) - [MODVQ.US - MODIVCARE INC](https://longbridge.com/zh-HK/quote/MODVQ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | ModivCare Inc. 注销其普通股 | ModivCare Inc. 宣布在第 11 章破产的预先安排的联合重组计划下，注销并退市其普通股。这一举措导致所有未偿还股份被取消，记录上不再有任何持有者。因此，该公司将不再需要提交定期报告 | [Link](https://longbridge.com/zh-HK/news/271030794.md) | | Quartix Technologies 称，FRC 已结束对 Quartix 会计处理的审查 | Quartix Technologies PLC：QUARTIX TECHNOLOGIES PLC - FRC 完成对 QUARTIX 会计处理的审查 QUARTIX TECHNOLOGIES PLC - FRC 同意将跟踪系统归类为根据 | [Link](https://longbridge.com/zh-HK/news/275565618.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。